Tags

Type your tag names separated by a space and hit enter

Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
Int J Antimicrob Agents. 2010 Jul; 36(1):58-65.IJ

Abstract

The aim of this study was to compare more conclusively the efficacy and safety of moxifloxacin, a new respiratory fluoroquinolone antibiotic, with beta-lactam-based standard therapy, which has been reported to possess good efficacy for community-acquired pneumonia (CAP). A meta-analysis of randomised controlled trials (RCTs) identified in PubMed, the Cochrane Library and Embase was performed. Seven RCTs, involving 3903 patients, were included in the meta-analysis. Moxifloxacin monotherapy was associated with similar clinical treatment success rates [clinically evaluable population, odds ratio (OR)=1.15, 95% confidence interval (CI) 0.81-1.64; intention-to-treat population, OR=1.11, 95% CI 0.86-1.42] and similar mortality (OR=0.98, 95% CI 0.66-1.46) compared with beta-lactam-based standard therapy for CAP. Microbiological treatment success rates in the moxifloxacin group were significantly higher than in the beta-lactam-based therapy group with a statistical margin (OR=1.69, 95% CI 1.02-2.80). No difference was found regarding the incidence of adverse events and serious adverse events between moxifloxacin and beta-lactam-based standard therapy. This meta-analysis provides evidence that moxifloxacin not only can be used as effectively and safely as beta-lactam-based standard therapy for CAP but also possesses a favourable pathogen eradication rate. The once-daily dosing of moxifloxacin monotherapy may be a useful alternative for beta-lactam-based standard therapy.

Authors+Show Affiliations

R&D Center of New Drugs, School of Pharmacy, Second Military Medical University, 325 Guo He Road, Shanghai 200433, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Meta-Analysis
Randomized Controlled Trial

Language

eng

PubMed ID

20400271

Citation

An, Mao Mao, et al. "Moxifloxacin Monotherapy Versus Beta-lactam-based Standard Therapy for Community-acquired Pneumonia: a Meta-analysis of Randomised Controlled Trials." International Journal of Antimicrobial Agents, vol. 36, no. 1, 2010, pp. 58-65.
An MM, Zou Z, Shen H, et al. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;36(1):58-65.
An, M. M., Zou, Z., Shen, H., Gao, P. H., Cao, Y. B., & Jiang, Y. Y. (2010). Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. International Journal of Antimicrobial Agents, 36(1), 58-65. https://doi.org/10.1016/j.ijantimicag.2010.03.010
An MM, et al. Moxifloxacin Monotherapy Versus Beta-lactam-based Standard Therapy for Community-acquired Pneumonia: a Meta-analysis of Randomised Controlled Trials. Int J Antimicrob Agents. 2010;36(1):58-65. PubMed PMID: 20400271.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. AU - An,Mao Mao, AU - Zou,Zui, AU - Shen,Hui, AU - Gao,Ping Hui, AU - Cao,Yong Bing, AU - Jiang,Yuan Ying, Y1 - 2010/04/18/ PY - 2010/02/08/received PY - 2010/02/25/revised PY - 2010/03/04/accepted PY - 2010/4/20/entrez PY - 2010/4/20/pubmed PY - 2010/8/14/medline SP - 58 EP - 65 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 36 IS - 1 N2 - The aim of this study was to compare more conclusively the efficacy and safety of moxifloxacin, a new respiratory fluoroquinolone antibiotic, with beta-lactam-based standard therapy, which has been reported to possess good efficacy for community-acquired pneumonia (CAP). A meta-analysis of randomised controlled trials (RCTs) identified in PubMed, the Cochrane Library and Embase was performed. Seven RCTs, involving 3903 patients, were included in the meta-analysis. Moxifloxacin monotherapy was associated with similar clinical treatment success rates [clinically evaluable population, odds ratio (OR)=1.15, 95% confidence interval (CI) 0.81-1.64; intention-to-treat population, OR=1.11, 95% CI 0.86-1.42] and similar mortality (OR=0.98, 95% CI 0.66-1.46) compared with beta-lactam-based standard therapy for CAP. Microbiological treatment success rates in the moxifloxacin group were significantly higher than in the beta-lactam-based therapy group with a statistical margin (OR=1.69, 95% CI 1.02-2.80). No difference was found regarding the incidence of adverse events and serious adverse events between moxifloxacin and beta-lactam-based standard therapy. This meta-analysis provides evidence that moxifloxacin not only can be used as effectively and safely as beta-lactam-based standard therapy for CAP but also possesses a favourable pathogen eradication rate. The once-daily dosing of moxifloxacin monotherapy may be a useful alternative for beta-lactam-based standard therapy. SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/20400271/Moxifloxacin_monotherapy_versus_beta_lactam_based_standard_therapy_for_community_acquired_pneumonia:_a_meta_analysis_of_randomised_controlled_trials_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(10)00133-0 DB - PRIME DP - Unbound Medicine ER -